United Therapeutics Corporation (UTHR) : Consonance Capital Management Lp added new position in United Therapeutics Corporation during the most recent quarter end. The investment management firm now holds 418,700 shares of United Therapeutics Corporation which is valued at $52,417,053 , the company said in a statement filed on Aug 15, 2016 with the SEC.United Therapeutics Corporation makes up approximately 6.27% of Consonance Capital Management Lp’s portfolio.
Other Hedge Funds, Including , Arrowstreet Capital Limited Partnership sold out all of its stake in UTHR during the most recent quarter. The investment firm sold 72,807 shares of UTHR which is valued $9,114,708.Pinebridge Investments boosted its stake in UTHR in the latest quarter, The investment management firm added 362 additional shares and now holds a total of 3,025 shares of United Therapeutics Corporation which is valued at $378,700. United Therapeutics Corporation makes up approx 0.02% of Pinebridge Investments’s portfolio.Globeflex Capital L P boosted its stake in UTHR in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 13,660 shares of United Therapeutics Corporation which is valued at $1,710,095. United Therapeutics Corporation makes up approx 0.44% of Globeflex Capital L P’s portfolio.Thompson Siegel Walmsley boosted its stake in UTHR in the latest quarter, The investment management firm added 331,476 additional shares and now holds a total of 567,786 shares of United Therapeutics Corporation which is valued at $71,126,552. United Therapeutics Corporation makes up approx 1.07% of Thompson Siegel Walmsley’s portfolio.Mizuho Trust Banking Ltd. reduced its stake in UTHR by selling 2,416 shares or 3.46% in the most recent quarter. The Hedge Fund company now holds 67,503 shares of UTHR which is valued at $8,428,425. United Therapeutics Corporation makes up approx 0.03% of Mizuho Trust Banking Ltd.’s portfolio.
United Therapeutics Corporation opened for trading at $122.75 and hit $123.47 on the upside on Thursday, eventually ending the session at $123.21, with a gain of 0.76% or 0.93 points. The heightened volatility saw the trading volume jump to 4,20,082 shares. Company has a market cap of $5,356 M.
On the company’s financial health, United Therapeutics Corporation reported $4.55 EPS for the quarter, beating the analyst consensus estimate by $ 1.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $3.52. The company had revenue of $412.60 million for the quarter, compared to analysts expectations of $395.00 million. The company’s revenue was up 18.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.55 EPS.
Many Wall Street Analysts have commented on United Therapeutics Corporation. Shares were Downgraded by H.C. Wainwright on Jun 15, 2016 to ” Neutral” and Lowered the Price Target to $ 95 from a previous price target of $175 .
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.